Endothelial cells and fibroblasts amplify the arthritogenic type I IFN response in murine lyme disease and are major sources of chemokines in Borrelia burgdorferi-infected joint tissue

Journal of Immunology

Volumn 189, Issue 5, 2012, Pages 2488-2501

  Lochhead, Robert B ^a   Sonderegger, F Lynn ^a   Ma, Ying ^a   Brewster, James E ^a   Cornwall, Doug ^a   Maylor Hagen, Heather ^a   Miller, Jennifer C ^a,c   Zachary, James F ^b   Weis, John H ^a   Weis, Janis J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; INTERFERON; INTERFERON RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BORRELIA BURGDORFERI; CELL INFILTRATION; CELL LINEAGE; CELL SELECTION; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; EX VIVO STUDY; FIBROBLAST; GENE; HETEROZYGOSITY; INFLAMMATORY INFILTRATE; LYME DISEASE; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TYPE IFN RECEPTOR GENE;

ANIMALS; ANKLE JOINT; ARTHRITIS, EXPERIMENTAL; BORRELIA BURGDORFERI; CELLS, CULTURED; CHEMOKINES; FIBROBLASTS; INTERFERON TYPE I; LYME DISEASE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID CELLS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84865441928     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201095     Document Type: Article

References (62)

1. Steere, A. C., and L. Glickstein. 2004. Elucidation of Lyme arthritis. Nat. Rev. Immunol. 4: 143-152.
2. Steere, A. C., R. T. Schoen, and E. Taylor. 1987. The clinical evolution of Lyme arthritis. Ann. Intern. Med. 107: 725-731.
3. Barthold, S. W., D. H. Persing, A. L. Armstrong, and R. A. Peeples. 1991. Kinetics of Borrelia burgdorferi dissemination and evolution of disease after intradermal inoculation of mice. Am. J. Pathol. 139: 263-273.
4. Barthold, S. W., D. S. Beck, G. M. Hansen, G. A. Terwilliger, and K. D. Moody. 1990. Lyme borreliosis in selected strains and ages of laboratory mice. J. Infect. Dis. 162: 133-138.
5. Radolf, J. D., M. J. Caimano, B. Stevenson, and L. T. Hu. 2012. Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes. Nat. Rev. Microbiol. 10: 87-99.
6. Weis, J. J., and L. K. Bockenstedt. 2010. Host response. In Borrelia; Molecular Biology, Host Interaction and Pathogenesis. D. S. Samuels and J. D. Radolf, eds. Caister Academinc Press, Norfolk, United Kingdom, p. 433-466.
7. Brown, C. R., A. Y. Lai, S. T. Callen, V. A. Blaho, J. M. Hughes, and W. J. Mitchell. 2008. Adenoviral delivery of interleukin-10 fails to attenuate experimental Lyme disease. Infect. Immun. 76: 5500-5507.
8. Brown, J. P., J. F. Zachary, C. Teuscher, J. J.Weis, and R. M.Wooten. 1999. Dual role of interleukin-10 in murine Lyme disease: regulation of arthritis severity and host defense. Infect. Immun. 67: 5142-5150.
9. Crandall, H., D. M. Dunn, Y. Ma, R. M. Wooten, J. F. Zachary, J. H. Weis, R. B. Weiss, and J. J. Weis. 2006. Gene expression profiling reveals unique pathways associated with differential severity of lyme arthritis. J. Immunol. 177: 7930-7942.
10. Brown, C. R., and S. L. Reiner. 1999. Experimental lyme arthritis in the absence of interleukin-4 or gamma interferon. Infect. Immun. 67: 3329-3333.
11. Sonderegger, F. L., Y. Ma, H. Maylor-Hagan, J. Brewster, X. Huang, G. J. Spangrude, J. F. Zachary, J. H. Weis, and J. J. Weis. 2012. Localized production of IL-10 suppresses early inflammatory cell infiltration and subsequent development of IFN-γ-mediated Lyme arthritis. J. Immunol. 188: 1381-1393.
12. Wang, X., Y. Ma, A. Yoder, H. Crandall, J. F. Zachary, R. S. Fujinami, J. H. Weis, and J. J. Weis. 2008. T cell infiltration is associated with increased Lyme arthritis in TLR2-/- mice. FEMS Immunol. Med. Microbiol. 52: 124-133.
13. Miller, J. C., Y. Ma, J. Bian, K. C. Sheehan, J. F. Zachary, J. H. Weis, R. D. Schreiber, and J. J. Weis. 2008. A critical role for type I IFN in arthritis development following Borrelia burgdorferi infection of mice. J. Immunol. 181: 8492-8503.
14. Santiago-Raber, M. L., R. Baccala, K. M. Haraldsson, D. Choubey, T. A. Stewart, D. H. Kono, and A. N. Theofilopoulos. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788.
15. Wilson, L. E., D. Widman, S. H. Dikman, and P. D. Gorevic. 2002. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum. 32: 163-173.
16. Pestka, S. 2007. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282: 20047-20051.
17. van der Pouw Kraan, T. C., C. A. Wijbrandts, L. G. van Baarsen, A. E. Voskuyl, F. Rustenburg, J. M. Baggen, S. M. Ibrahim, M. Fero, B. A. Dijkmans, P. P. Tak, and C. L. Verweij. 2007. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 66: 1008-1014.
18. van Baarsen, L. G., C. A. Wijbrandts, F. Rustenburg, T. Cantaert, T. C. van der Pouw Kraan, D. L. Baeten, B. A. Dijkmans, P. P. Tak, and C. L. Verweij. 2010. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res. Ther. 12: R11.
19. Mavragani, C. P., D. T. La, W. Stohl, and M. K. Crow. 2010. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 62: 392-401.
20. Müller, U., U. Steinhoff, L. F. Reis, S. Hemmi, J. Pavlovic, R. M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264: 1918-1921.
21. Yarilina, A., E. DiCarlo, and L. B. Ivashkiv. 2007. Suppression of the effector phase of inflammatory arthritis by double-stranded RNA is mediated by type I IFNs. J. Immunol. 178: 2204-2211.
22. Wooten, R. M., Y. Ma, R. A. Yoder, J. P. Brown, J. H. Weis, J. F. Zachary, C. J. Kirschning, and J. J. Weis. 2002. Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi. J. Immunol. 168: 348-355.
23. Huang, X., L. J. Pierce, P. A. Cobine, D. R. Winge, and G. J. Spangrude. 2009. Copper modulates the differentiation of mouse hematopoietic progenitor cells in culture. Cell Transplant. 18: 887-897.
24. Ma, Y., J. C. Miller, H. Crandall, E. T. Larsen, D. M. Dunn, R. B. Weiss, M. Subramanian, J. H. Weis, J. F. Zachary, C. Teuscher, and J. J. Weis. 2009. Interval-specific congenic lines reveal quantitative trait loci with penetrant lyme arthritis phenotypes on chromosomes 5, 11, and 12. Infect. Immun. 77: 3302-3311.
25. Miller, J. C., H. Maylor-Hagen, Y. Ma, J. H. Weis, and J. J. Weis. 2010. The Lyme disease spirochete Borrelia burgdorferi utilizes multiple ligands, including RNA, for interferon regulatory factor 3-dependent induction of type I interferon-responsive genes. Infect. Immun. 78: 3144-3153.
26. Ma, Y., K. P. Seiler, K. F. Tai, L. Yang, M. Woods, and J. J. Weis. 1994. Outer surface lipoproteins of Borrelia burgdorferi stimulate nitric oxide production by the cytokine-inducible pathway. Infect. Immun. 62: 3663-3671.
27. Morrison, T. B., Y. Ma, J. H. Weis, and J. J. Weis. 1999. Rapid and sensitive quantification of Borrelia burgdorferi-infected mouse tissues by continuous fluorescent monitoring of PCR. J. Clin. Microbiol. 37: 987-992.
28. Sheehan, K. C., K. S. Lai, G. P. Dunn, A. T. Bruce, M. S. Diamond, J. D. Heutel, C. Dungo-Arthur, J. A. Carrero, J. M. White, P. J. Hertzog, and R. D. Schreiber. 2006. Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26: 804-819.
29. Meerpohl, H. G., M. L. Lohmann-Matthes, and H. Fischer. 1976. Studies on the activation of mouse bone marrow-derived macrophages by the macrophage cytotoxicity factor (MCF). Eur. J. Immunol. 6: 213-217.
30. Weis, J. J., B. A. McCracken, Y. Ma, D. Fairbairn, R. J. Roper, T. B. Morrison, J. H. Weis, J. F. Zachary, R. W. Doerge, and C. Teuscher. 1999. Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease. J. Immunol. 162: 948-956.
31. Palucka, A. K., J. P. Blanck, L. Bennett, V. Pascual, and J. Banchereau. 2005. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl. Acad. Sci. USA 102: 3372-3377.
32. Meissner, N., S. Swain, K. McInnerney, S. Han, and A. G. Harmsen. 2010. Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. Am. J. Pathol. 176: 2806-2818.
33. Siednienko, J., T. Gajanayake, K. A. Fitzgerald, P. Moynagh, and S. M. Miggin. 2011. Absence of MyD88 results in enhanced TLR3-dependent phosphorylation of IRF3 and increased IFN-β and RANTES production. J. Immunol. 186: 2514-2522.
34. Petzke, M. M., A. Brooks, M. A. Krupna, D. Mordue, and I. Schwartz. 2009. Recognition of Borrelia burgdorferi, the Lyme disease spirochete, by TLR7 and TLR9 induces a type I IFN response by human immune cells. J. Immunol. 183: 5279-5292.
35. Salazar, J. C., S. Duhnam-Ems, C. La Vake, A. R. Cruz, M. W. Moore, M. J. Caimano, L. Velez-Climent, J. Shupe, W. Krueger, and J. D. Radolf. 2009. Activation of human monocytes by live Borrelia burgdorferi generates TLR2-dependent and -independent responses which include induction of IFN-beta. PLoS Pathog. 5: e1000444.
36. Cervantes, J. L., S. M. Dunham-Ems, C. J. La Vake, M. M. Petzke, B. Sahay, T. J. Sellati, J. D. Radolf, and J. C. Salazar. 2011. Phagosomal signaling by Borrelia burgdorferi in human monocytes involves Toll-like receptor (TLR) 2 and TLR8 cooperativity and TLR8-mediated induction of IFN-beta. Proc. Natl. Acad. Sci. USA 108: 3683-3688.
37. Cruz, A. R., M. W. Moore, C. J. La Vake, C. H. Eggers, J. C. Salazar, and J. D. Radolf. 2008. Phagocytosis of Borrelia burgdorferi, the Lyme disease spirochete, potentiates innate immune activation and induces apoptosis in human monocytes. Infect. Immun. 76: 56-70.
38. Shin, O. S., R. R. Isberg, S. Akira, S. Uematsu, A. K. Behera, and L. T. Hu. 2008. Distinct roles for MyD88 and Toll-like receptors 2, 5, and 9 in phagocytosis of Borrelia burgdorferi and cytokine induction. Infect. Immun. 76: 2341-2351.
39. Bolz, D. D., R. S. Sundsbak, Y. Ma, S. Akira, C. J. Kirschning, J. F. Zachary, J. H. Weis, and J. J. Weis. 2004. MyD88 plays a unique role in host defense but not arthritis development in Lyme disease. J. Immunol. 173: 2003-2010.
40. Auerbuch, V., D. G. Brockstedt, N. Meyer-Morse, M. O'Riordan, and D. A. Portnoy. 2004. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J. Exp. Med. 200: 527-533.
41. Lee, P. Y., J. S. Weinstein, D. C. Nacionales, P. O. Scumpia, Y. Li, E. Butfiloski, N. van Rooijen, L. Moldawer, M. Satoh, and W. H. Reeves. 2008. A novel type I IFN-producing cell subset in murine lupus. J. Immunol. 180: 5101-5108.
42. Seo, S. U., H. J. Kwon, H. J. Ko, Y. H. Byun, B. L. Seong, S. Uematsu, S. Akira, and M. N. Kweon. 2011. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog. 7: e1001304.
43. Müller-Ladner, U., J. Kriegsmann, B. N. Franklin, S. Matsumoto, T. Geiler, R. E. Gay, and S. Gay. 1996. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am. J. Pathol. 149: 1607-1615.
44. Pilling, D., T. Fan, D. Huang, B. Kaul, and R. H. Gomer. 2009. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One 4: e7475.
45. Wooten, R. M., T. B. Morrison, J. H. Weis, S. D. Wright, R. Thieringer, and J. J. Weis. 1998. The role of CD14 in signaling mediated by outer membrane lipoproteins of Borrelia burgdorferi. J. Immunol. 160: 5485-5492.
46. Narayan, K., D. Dail, L. Li, D. Cadavid, S. Amrute, P. Fitzgerald-Bocarsly, and A. R. Pachner. 2005. The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis. Ann. Neurol. 57: 813-823.
47. Müllegger, R. R., T. K. Means, J. J. Shin, M. Lee, K. L. Jones, L. J. Glickstein, A. D. Luster, and A. C. Steere. 2007. Chemokine signatures in the skin disorders of Lyme borreliosis in Europe: predominance of CXCL9 and CXCL10 in erythema migrans and acrodermatitis and CXCL13 in lymphocytoma. Infect. Immun. 75: 4621-4628.
48. Olson, C. M., Jr., T. C. Bates, H. Izadi, J. D. Radolf, S. A. Huber, J. E. Boyson, and J. Anguita. 2009. Local production of IFN-gamma by invariant NKT cells modulates acute Lyme carditis. J. Immunol. 182: 3728-3734.
49. Steere, A. C., J. Coburn, and L. Glickstein. 2004. The emergence of Lyme disease. J. Clin. Invest. 113: 1093-1101.
50. Moore, M. W., A. R. Cruz, C. J. LaVake, A. L. Marzo, C. H. Eggers, J. C. Salazar, and J. D. Radolf. 2007. Phagocytosis of Borrelia burgdorferi and Treponema pallidum potentiates innate immune activation and induces gamma interferon production. Infect. Immun. 75: 2046-2062.
51. Hawley, K. L., C. M. Olson, Jr., J. M. Iglesias-Pedraz, N. Navasa, J. L. Cervantes, M. J. Caimano, H. Izadi, R. R. Ingalls, U. Pal, J. C. Salazar, et al. 2012. CD14 cooperates with complement receptor 3 to mediate MyD88-independent phagocytosis of Borrelia burgdorferi. Proc. Natl. Acad. Sci. USA 109: 1228-1232.
52. Zhou, X., M. R. Miller, M. Motaleb, N. W. Charon, and P. He. 2008. Spent culture medium from virulent Borrelia burgdorferi increases permeability of individually perfused microvessels of rat mesentery. PLoS One 3: e4101.
53. Solodova, E., J. Jablonska, S. Weiss, and S. Lienenklaus. 2011. Production of IFN-β during Listeria monocytogenes infection is restricted to monocyte/macrophage lineage. PLoS One 6: e18543.
54. Laragione, T., M. Brenner, B. Sherry, and P. S. Gulko. 2011. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum. 63: 3274-3283.
55. Brown, C. R., V. A. Blaho, and C. M. Loiacono. 2003. Susceptibility to experimental Lyme arthritis correlates with KC and monocyte chemoattractant protein-1 production in joints and requires neutrophil recruitment via CXCR2. J. Immunol. 171: 893-901.
56. Montgomery, R. R., C. J. Booth, X. Wang, V. A. Blaho, S. E. Malawista, and C. R. Brown. 2007. Recruitment of macrophages and polymorphonuclear leukocytes in Lyme carditis. Infect. Immun. 75: 613-620.
57. Harman, M. W., S. M. Dunham-Ems, M. J. Caimano, A. A. Belperron, L. K. Bockenstedt, H. C. Fu, J. D. Radolf, and C. W. Wolgemuth. 2012. The heterogeneous motility of the Lyme disease spirochete in gelatin mimics dissemination through tissue. Proc. Natl. Acad. Sci. USA 109: 3059-3064.
58. Moriarty, T. J., M. U. Norman, P. Colarusso, T. Bankhead, P. Kubes, and G. Chaconas. 2008. Real-time high resolution 3D imaging of the lyme disease spirochete adhering to and escaping from the vasculature of a living host. PLoS Pathog. 4: e1000090.
59. Coburn, J., J. R. Fischer, and J. M. Leong. 2005. Solving a sticky problem: new genetic approaches to host cell adhesion by the Lyme disease spirochete. Mol. Microbiol. 57: 1182-1195.
60. Chmielewski, T., and S. Tylewska-Wierzbanowska. 2010. Interactions between Borrelia burgdorferi and mouse fibroblasts. Pol. J. Microbiol. 59: 157-160.
61. Tossberg, J. T., P. S. Crooke, M. A. Henderson, S. Sriram, D. Mrelashvili, S. Chitnis, C. Polman, S. Vosslamber, C. L. Verweij, N. J. Olsen, and T. M. Aune. 2012. Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis. Genes Immun. 13: 146-154.
62. Vosslamber, S., H. G. Raterman, T. C. van der Pouw Kraan, M. W. Schreurs, B. M. von Blomberg, M. T. Nurmohamed, W. F. Lems, B. A. Dijkmans, A. E. Voskuyl, and C. L. Verweij. 2011. Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann. Rheum. Dis. 70: 1153-1159.